[Intracameral bevacizumab (Avastin®) in the management of neovascular glaucoma surgery].
To describe a case series of neovascular glaucoma treated with intracameral bevacizumab prior to filtering surgery. Descriptive, retrospective case series. Five eyes of 5 patients with neovascular glaucoma due to any cause candidates to filtering surgery who had previously received an injection of intracameral bevacizumab (1.25 mg/0.05 ml) as treatment for neovascularization of anterior chamber. Results observed one week and 4 weeks postsurgery are reported. Bevacizumab produced regression of the angle neovascularization and the intraocular pressure. Only one case of postoperative bleeding was detected. Intracameral bevacizumab prior to filtering surgery of neovascular glaucoma diminished the neovascularization and intraocular pressure after 4 weeks of its administration and was effective in preventing intraoperative and postoperative bleeding. It also constitutes a promising way of investigation to prevent surgical complications.